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in Vaccinated Child 
with Cochlear 
Implant 
To the Editor: Approximately 
100,000 persons worldwide have 
received cochlear implants for hearing 
loss, and more children now receive 
them than ever (1). Such children 
have a >30-fold increased risk for 
pneumococcal meningitis than the 
background rate (1,2). During 2006–
2010, children born in the United 
Kingdom were offered the 7-valent 
pneumococcal conjugate vaccine 
(PCV7) at 2, 4, and 13 months of age 
(3). Those at high risk for invasive 
pneumococcal disease (IPD) were 
additionally offered the 23-valent 
pneumococcal polysaccharide vaccine 
(PPV23) at 2–5 years (3). We 
describe a fully vaccinated child 
with a cochlear implant in whom 
recurrent pneumococcal meningitis 
developed, caused by a vaccine 
serotype (i.e., vaccine failure). The 
child continues to have nonprotective 
antibody concentrations against the 
infecting serotype, despite further 
pneumococcal vaccination.
A previously healthy, appro-
priately vaccinated 23-month-old 
girl (Table) had a cochlear device 
implanted in the right ear after 
receiving (through the universal 
newborn hearing screening program) 
a diagnosis of profound, bilateral, 
sensorineural deafness. Two weeks 
later, she exhibited fever, lethargy, and 
drowsiness. On hospital admission, 
she had a peripheral blood leukocyte 
count of 19.3 × 109 cells/L, a 
neutrophil count of 17.0 × 109 cells/L, 
and C-reactive protein level 75 mg/L. 
Meningitis was diagnosed, and she 
received intravenous ceftriaxone but 
was too ill for a lumbar puncture. 
Blood cultures subsequently grew fully 
sensitive Streptococcus pneumoniae, 
later confi rmed as serotype 4 by the 
national reference laboratory. She was 
discharged after 14 days of receiving 
intravenous antimicrobial drugs 
without complications.
At 24 months, she received a 
fourth dose of PCV7. Blood tests 1 
month later showed good antibody 
responses to 6 PCV7 serotypes but not 
to serotype 4, which did not reach the 
putative protective level of >0.35 μg/
mL antibody threshold (Table). At 28 
months, she received 1 dose of PPV23 
per national guidelines (3). Four 
months later, she was brought to the 
hospital with fever, rigors, drowsiness, 
and vomiting. Blood tests showed a 
leukocyte count of 24.4 × 109 cells/L, 
neutrophil count of 21.6 × 109 cells/L, 
and C-reactive protein level of 272 
mg/L. Lumbar puncture performed 
the next day showed 890 leukocytes/
mL (predominantly polymorphs), 
cerebrospinal fl uid glucose level <1.1 
mmol/L, protein level of 1.0 g/L, 
gram-positive diplococci on Gram 
staining, and positive PCR results for 
pneumococci, although cerebrospinal 
fl uid culture was negative.
A blood culture grew fully 
sensitive S. pneumoniae, also 
confi rmed by the national reference 
laboratory as serotype 4. She 
recovered after receiving intravenous 
ceftriaxone and oral rifampin for 2 
weeks, followed by 4 weeks of oral 
amoxicillin and rifampin. She then 
received prophylactic oral penicillin 
for maintenance. Subsequently, an 
abdominal ultrasound confi rmed 
the presence of a spleen, and her 
immunoglobulin concentrations were 
in the normal range. At 35 months, she 
received another dose of PCV7, and a 
blood test 1 month later showed variable 
but high responses to 6 of the PCV7 
serotypes and no response to serotype 
4 (Table). Moreover, nasopharyngeal 
swab specimens, obtained when 
the patient was 39 months old and 
receiving penicillin prophylaxis, were 
positive for serotype 4.
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We described 8 previously 
healthy children with serotype-
specifi c immune unresponsiveness 
after IPD, although a second IPD 
episode did not develop in these 
children (4). This phenomenon may 
result from large pneumococcal 
polysaccharide loads that deplete 
the memory B-cell pool and 
cause immune paralysis (4,5). 
In immunogenicity studies, 
some infants (1%–3%) remain 
unresponsive to conjugate vaccines 
(5). In a randomized controlled 
trial of PPV23 in 50–85-year-old 
persons, 3 vaccinated persons with 
culture-confi rmed IPD had adequate 
pre- and postvaccination antibody 
concentrations to all but the infecting 
serotype, suggesting that they 
were unresponsive to the infecting 
serotype before vaccination (6). In 
infants, recent randomized controlled 
trials have found that nasopharyngeal 
carriage at fi rst dose of PCV7 
resulted in signifi cantly lower IgG 
responses to that specifi c serotype 
than occurred with noncarriers or 
carriers of other serotypes, possibly 
because of high carriage–induced 
polysaccharide loads (7,8). Moreover, 
unresponsiveness was only partially 
overcome by the 12-month PCV7 
booster (7).
This case raises key questions 
regarding long-term clinical manage-
ment of children with serotype-
specifi c immune unresponsiveness 
after vaccination or infection. The 
case is further complicated by the 
patient’s cochlear implant, which may 
have been the source of infection (9), 
as well as evidence of nasopharyngeal 
carriage while the patient was receiving 
antimicrobial drug prophylaxis and 
recurrence of meningitis caused by 
the same serotype. However, her 
ability to respond to the other 6 PCV7 
serotypes, normal immunoglobulin 
concentrations, no previous history of 
recurrent infections, and presence of a 
spleen all provide evidence against an 
underlying immune problem.
Further pneumococcal vaccina-
tion of this patient is unlikely to 
reverse the unresponsiveness, which 
may persist for years (4,5). Studies 
to clarify the immune mechanisms 
underlying unresponsiveness and 
strategies to reverse this phenomenon 
are, therefore, urgently warranted. 
In the meantime, we recommend 
that the infecting pneumococcal 
serotype be determined in children 
with IPD and that, when possible, 
those infected with a vaccine-related 
strain (particularly children with 
risk factors) have serotype-specifi c 
pneumococcal antibodies measured 
after infection.  Appropriate measures 
to prevent recurrent IPD should 
also be taken, such as removal of 
potentially infected devices or long-
term prophylaxis with antimicrobial 
drugs. 
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4 6B 9V 14 18C 19F 23F
1.9 PCV7 dose 1        
3.9 PCV7 dose 2        
13.4 PCV7 dose 3        
22.8 Cochlear implant        
23.4 Pneumococcal meningitis (episode 1)        
24.4 PCV7 dose 4        
25.6 Pneumococcal serologic testing 0.12 27.6 23.0 36.9 13.8 57.0 41.1 
27.8 PPV23 dose 1        
28.8 Pneumococcal serologic testing 0.18 14.2 13.1 30.4 11.4 11.7 32.0 
32.0 Pneumococcal meningitis (episode 2)        
35.1 PCV7 dose 5        
36.1 Pneumococcal serologic testing 0.20 18.40 7.12 12.50 12.40 2.78 37.1 
39.0 PCR positive nasopharyngeal swab 
specimen for Streptococcus pneumoniae
serotype 4 
       
*PCV7, 7-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine. Blank spaces indicate not tested. 
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African Swine Fever 
Virus Strain 
Georgia 2007/1 in 
Ornithodoros 
erraticus Ticks
To the Editor: African swine 
fever virus (ASFV) causes a notifi able 
disease in domestic pigs for which 
no treatment or vaccine is available, 
resulting in a mortality rate of <100%. 
In 2007 ASFV was detected in the 
Caucasus region, fi rst in Georgia and 
subsequently in Armenia, Azerbaijan, 
and many parts of Russia, including 
regions that border other countries in 
Europe and Asia (1).
Most fi eld strains of ASFV can 
persistently infect Ornithodoros ticks, 
including the species O. erraticus in 
southern Europe (2), and ASFV has 
been isolated from ticks collected 
>5 years after the last confi rmed 
case in an outbreak (3). These ticks 
can feed on alternative hosts, evade 
eradication attempts (such as acaricide 
application and fl amethrowers), 
and survive for up to 15 years (1). 
Although Ornithodoros species have 
been reported in the Caucasus region, 
their distribution is not well known 
(1). It is also not known if the Georgia 
2007/1 ASFV strain responsible for 
continuing outbreaks in the Caucasus 
region can replicate in ticks. Thus, 
we conducted a study to determine 
whether the Georgia 2007/1 isolate of 
ASFV can replicate in Ornithodoros 
ticks.
O. erraticus ticks from Alentejo, 
Portugal (provided by Fernando 
Boinas, Universidade Técnica de 
Lisboa in Lisbon, Portugal) were 
sorted into groups of 10 adults or fi fth-
instar nymphs, placed into 60-mL 
containers covered with nylon cloth 
(16-cm mesh), and maintained at 85% 
relative humidity and 27°C for 18 
months without feeding. Heparinized 
pig blood containing antibacterial 
drugs and fungicide (10 μL of 
streptomycin [10,000 IU/mL], 10 μL 
of amphotericin B [250 μg/mL], and 
5 μL of neomycin [10 mg/mL 0.9% 
NaCl]/mL of blood) was mixed with 
the Georgia 2007/1 isolate (4) or the 
OUR T88/1 isolate (5) as a positive 
control to obtain virus titers of 4 log10 
or 6 log10 50% hemadsorbing doses 
(HAD50)/mL blood. These titers were 
within the observed range in naturally 
infected pigs (6), and thus simulated 
the fi eld situation.
Ticks were fed infected blood by 
using a Hemotek membrane-feeding 
system (Discovery Workshops, 
Accrington, UK). Meal reservoirs 
were covered with stretched Parafi lm 
that was wiped with a thin fi lm 
of uninfected blood to encourage 
feeding. Pots of ticks were placed on 
the membrane and allowed to feed for 
20 minutes.
Immediately after and 3, 6, 9, 
and 12 weeks after feeding, 10 ticks 
from each feeding group were killed 
by freezing in dry ice. After being 
washed with a detergent solution and 
phosphate-buffered saline, ticks were 
placed individually in tubes with 200 
μL of RPMI medium (Sigma-Aldrich 
Company Ltd., Gillingham, UK), a 
3 mm-diameter stainless steel ball 
(Dejay Distribution Ltd., Launceston, 
UK), and 1-mm silicon carbide 
particles (Stratech Scientifi c Ltd, 
Newmarket, UK). They were then 
homogenized by shaking for 5 cycles 
of 3 minutes at 25-Hz frequency using 
a TissueLyser (QIAGEN, Valencia, 
CA, USA). To complete a 1-mL 
volume, 800 μL of RPMI medium was 
added to the tubes after centrifuging 
2× for 30 seconds at 2,000 rpm. 
Supernatants were transferred to fresh 
tubes and centrifuged for 5 minutes at 
1,000 × g.
Virus titers were estimated on 
porcine bone marrow cells (7) and 
expressed as log10 HAD50 per tick. 
Previous studies suggest that it takes 
3–4 weeks for ticks to completely 
digest and clear ingested blood and 
that virus isolated after this period is 
due to viral replication (5,6). A general 
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